This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Abclon Inc., University of Pennsylvania. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 11 
1 out of 2,663 
Years Active: 2025-2026
Title: Hyun-Jong Lee: Innovator in Cancer Therapy
Introduction
Hyun-Jong Lee is a prominent inventor based in Incheon, South Korea. He has made significant contributions to the field of cancer therapy through his innovative research and development of therapeutic agents.
Latest Patents
Hyun-Jong Lee holds a patent for an "Anti-HER2 affibody and switchable chimeric antigen receptor using same as switch molecule." This patent discloses an anti-HER2 affibody and a switch molecule that includes a cotinine-conjugated anti-HER2 affibody. When applied in combination with Cot-sCART, the cotinine-conjugated anti-HER2 affibody reacts with HER2-positive cells to induce immune cell activity. This innovation finds advantageous applications as switch molecules in sCART therapeutic agents. He has 1 patent to his name.
Career Highlights
Hyun-Jong Lee has established himself as a key figure in his field, working at Abclon Inc., where he continues to push the boundaries of cancer treatment. His work focuses on developing novel therapeutic strategies that enhance the efficacy of existing treatments.
Collaborations
Some of his notable coworkers include Ki Hyun Kim and Jong-Seo Lee, who contribute to the collaborative efforts in advancing cancer therapies.
Conclusion
Hyun-Jong Lee's innovative work in developing anti-HER2 affibodies represents a significant advancement in cancer therapy. His contributions are paving the way for more effective treatments for patients with HER2-positive cancers.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile